{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:24Z","timestamp":1783401324709,"version":"3.54.6"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Medical and Health Science and Technology Project of Shandong Province","award":["202303111704"],"award-info":[{"award-number":["202303111704"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08220-w","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:49:20Z","timestamp":1781527760000},"page":"4233-4239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pilot study on the efficacy and mechanism of telitacicept in systemic lupus erythematosus with antiphospholipid syndrome"],"prefix":"10.1007","volume":"45","author":[{"given":"Haihui","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-5920","authenticated-orcid":false,"given":"Jing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"8220_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069717","volume":"380","author":"JS Knight","year":"2023","unstructured":"Knight JS, Branch DW, Ortel TL (2023) Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ 380:e069717. https:\/\/doi.org\/10.1136\/bmj-2021-069717","journal-title":"BMJ"},{"key":"8220_CR2","doi-asserted-by":"publisher","unstructured":"Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-Garc\u00eda A (2022) Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep 23(12):85.\u00a0https:\/\/doi.org\/10.1007\/s11926-021-01038-2","DOI":"10.1007\/s11926-021-01038-2"},{"key":"8220_CR3","doi-asserted-by":"publisher","unstructured":"Gaspar P, Sciascia S, Tektonidou MG (2024) Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations. Rheumatology (Oxford) 63(SI):SI24-SI36.\u00a0https:\/\/doi.org\/10.1093\/rheumatology\/kead571","DOI":"10.1093\/rheumatology\/kead571"},{"key":"8220_CR4","doi-asserted-by":"publisher","unstructured":"Dhillon S (2021) Telitacicept: First Approval. Drugs 81(14):1671\u20131675.\u00a0https:\/\/doi.org\/10.1007\/s40265-021-01591-1","DOI":"10.1007\/s40265-021-01591-1"},{"key":"8220_CR5","doi-asserted-by":"publisher","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, S\u00e1nchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677\u20132686.\u00a0https:\/\/doi.org\/10.1002\/art.34473","DOI":"10.1002\/art.34473"},{"key":"8220_CR6","doi-asserted-by":"publisher","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 4(2):295\u2013306.\u00a0https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01753.x","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"8220_CR7","doi-asserted-by":"publisher","unstructured":"D\u2019Ippolito S, Barbaro G, Paciullo C, Tersigni C, Scambia G, Di Simone N (2023) Antiphospholipid syndrome in pregnancy: new and old pathogenetic mechanisms. Int J Mol Sci 24(4):3195.\u00a0https:\/\/doi.org\/10.3390\/ijms24043195","DOI":"10.3390\/ijms24043195"},{"issue":"6","key":"8220_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43(6):666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"8220_CR9","doi-asserted-by":"publisher","unstructured":"M\u00f6ckel T, Basta F, Weinmann-Menke J, Schwarting A (2020) B cell activating factor (BAFF): structure, functions, autoimmunity and clinical implications in systemic lupus erythematosus (SLE). Autoimmun Rev 20(2):33333233, 102736. https:\/\/doi.org\/10.1016\/j.autrev.2020.102736","DOI":"10.1016\/j.autrev.2020.102736"},{"key":"8220_CR10","doi-asserted-by":"publisher","unstructured":"van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, Hu J, Huang C, Zhao J, Huang C, Mo H, Wei W, Lu F, Li J, Zhao D, Wang W, Li L, Zuraw Q, Wang X, Wang X, Fang J, Zhang F (2025) 18C010 Trial Investigators A phase 3 trial of telitacicept for systemic lupus erythematosus. N Engl J Med 393(15):1475\u20131485.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2414719","DOI":"10.1056\/NEJMoa2414719"},{"key":"8220_CR11","doi-asserted-by":"publisher","unstructured":"Zhou L, You Y, Cai S, Ye C, Dong L (2025) Effects of telitacicept in SLE patients with antiphospholipid antibody positivity: a retrospective self-controlled case series. Clin Rheumatol 44(6):2287\u20132297.\u00a0https:\/\/doi.org\/10.1007\/s10067-025-07411-1","DOI":"10.1007\/s10067-025-07411-1"},{"key":"8220_CR12","doi-asserted-by":"publisher","unstructured":"Reshetnyak T, Cheldieva F, Cherkasova M, Lila A, Nasonov E (2022) IgA antiphospholipid antibodies in antiphospholipid syndrome and systemic lupus erythematosus. Int J Mol Sci 23(16):9432.\u00a0https:\/\/doi.org\/10.3390\/ijms23169432","DOI":"10.3390\/ijms23169432"},{"key":"8220_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1145145","volume":"14","author":"Z Yun","year":"2023","unstructured":"Yun Z, Duan L, Liu X, Cai Q, Li C (2023) An update on the biologics for the treatment of antiphospholipid syndrome. Front Immunol 14:1145145. https:\/\/doi.org\/10.3389\/fimmu.2023.1145145","journal-title":"Front Immunol"},{"issue":"5","key":"8220_CR14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83962","volume":"17","author":"U Rizwanullah","year":"2025","unstructured":"Rizwanullah U, Abifaraj A, Shah S, Kausar R, Hummad H, Portillo Mu\u00f1oz CA, Hyderi FA, Chi Gomez LA, Urbina R, Niftalieva G, Vasquez Zelaya ED, Faraj M (2025) Long-term outcomes of rituximab therapy in autoimmune hemolytic anemia: a systematic review and meta-analysis. Cureus 17(5):e83962. https:\/\/doi.org\/10.7759\/cureus.83962","journal-title":"Cureus"},{"key":"8220_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/3226278","volume":"2023","author":"H Hasan","year":"2023","unstructured":"Hasan H, Surjancev I, Arnason JA, Garg S, Rose WN (2023) Corticosteroids, plasmapheresis, argatroban, rituximab, and sirolimus provided clinical benefit for catastrophic antiphospholipid syndrome in a patient with a history of heparin-induced thrombocytopenia. Case Rep Rheumatol 2023:3226278. https:\/\/doi.org\/10.1155\/2023\/3226278","journal-title":"Case Rep Rheumatol"},{"issue":"5","key":"8220_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2025.2484844","volume":"25","author":"M Radin","year":"2025","unstructured":"Radin M, Barinotti A, Galarza D, Cecchi I, Camerlo S, Vaccarino A, Roccatello D, Morotti A, Sciascia S (2025) Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now. Expert Opin Biol Ther 25(5):1\u20133. https:\/\/doi.org\/10.1080\/14712598.2025.2484844","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"8220_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keag150","volume":"65","author":"M Nikitsina","year":"2026","unstructured":"Nikitsina M, Ram\u00edrez Mart\u00edn M, Navarro-Joven C, Piunno S, Zolio L, Isenberg DA (2026) Assessment of the use of biologic drugs in the treatment of primary antiphospholipid syndrome. Rheumatology (Oxford) keag150. https:\/\/doi.org\/10.1093\/rheumatology\/keag150","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8220_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/03009742.2023.2247881","volume":"53","author":"J Dong","year":"2024","unstructured":"Dong J, Zhao L, Pan L, Wang H, Wang L (2024) Belimumab therapy for refractory immune thrombocytopenia in systemic lupus erythematosus patients with anti-phospholipid antibodies. Scand J Rheumatol 53(1):59\u201362. https:\/\/doi.org\/10.1080\/03009742.2023.2247881","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"8220_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-025-03584-x","volume":"27","author":"X Chen","year":"2025","unstructured":"Chen X, Hu L, Zhu L, Tu J, Gui J, Fang M, Sun L (2025) Prospective analysis of B cell subset dynamics following telitacicept treatment in systemic lupus erythematosus. Arthritis Res Ther 27(1):126. https:\/\/doi.org\/10.1186\/s13075-025-03584-x","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08220-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08220-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08220-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:01Z","timestamp":1783398421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08220-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8220"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08220-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"18 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}